Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action. The company’s head of external innovation and ...

The study’s primary endpoint was measured by at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) score at 16 weeks, which evaluates the extent and severity of the skin ...

Eczema affected me physically ... I got into a clinical trial of the biologic drug dupilumab (Dupixent). That was a game-changer. With that drug, I was finally able to start enjoying life.

What would you say are the biggest unmet needs in eczema at the moment? I'm one of the fortunate ones who has been a true success story on Dupixent, but there are many people out there for whom it ...

says she’d developed mild, infrequent quarter-sized patches on her skin throughout her life, but she didn’t realize they were eczema symptoms until her older daughter received an atopic ...

Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose 23.8% to 3.48 billion euros. Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma ...

and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:SNY) / Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Dupixent ...